Post by KStrategy&

uniQure has reached a significant milestone with AMT-130, its gene therapy for Huntington's disease, securing FDA alignment on key elements of the Accelerated Approval pathway. The FDA has agreed that data from ongoing Phase I/II trials can serve as the basis for a Biologics License Application (BLA), with the composite Unified Huntington’s Disease Rating Scale (cUHDRS) as an intermediate clinical endpoint. Interim data at 24 months showed promising results, including a slowing of disease progression and reductions in neurodegeneration markers. AMT-130, which has received RMAT designation, offers hope for patients with Huntington’s disease, a condition currently without treatments to slow its progression. #uniQure #AMT130 #HuntingtonsDisease #GeneTherapy #AcceleratedApproval #FDA #BLA #RMAT #cUHDRS #Neurodegeneration #MedicalBreakthrough #RegenerativeMedicine #HuntingtonsTreatment #ClinicalTrials #Neurotherapy #InnovativeTherapy #LifeChangingTreatment #HuntingtonsResearch #Humanteconomy #Humantec